1. Home
  2. MASI vs NUVL Comparison

MASI vs NUVL Comparison

Compare MASI & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Masimo Corporation

MASI

Masimo Corporation

HOLD

Current Price

$175.36

Market Cap

7.0B

Sector

Health Care

ML Signal

HOLD

Logo Nuvalent Inc.

NUVL

Nuvalent Inc.

HOLD

Current Price

$100.22

Market Cap

8.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MASI
NUVL
Founded
1989
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.0B
8.1B
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
MASI
NUVL
Price
$175.36
$100.22
Analyst Decision
Hold
Strong Buy
Analyst Count
6
15
Target Price
$184.25
$135.33
AVG Volume (30 Days)
2.0M
444.7K
Earning Date
03-30-2026
05-27-2026
Dividend Yield
N/A
N/A
EPS Growth
51.05
N/A
EPS
N/A
N/A
Revenue
$1,239,153,000.00
N/A
Revenue This Year
$8.59
N/A
Revenue Next Year
$7.60
$714.21
P/E Ratio
N/A
N/A
Revenue Growth
8.34
N/A
52 Week Low
$125.94
$55.54
52 Week High
$186.27
$113.02

Technical Indicators

Market Signals
Indicator
MASI
NUVL
Relative Strength Index (RSI) 75.42 43.80
Support Level $136.90 $98.65
Resistance Level N/A $106.97
Average True Range (ATR) 1.57 4.49
MACD 1.54 -0.18
Stochastic Oscillator 98.84 28.74

Price Performance

Historical Comparison
MASI
NUVL

About MASI Masimo Corporation

Masimo Corp is a technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.

About NUVL Nuvalent Inc.

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Share on Social Networks: